More on JANX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $17.32 |
|
|||
| Open | $17.27 | ||||
| 52 Wk High | $0.01 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $17.27 | ||||
| Day Low | $16.43 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 765,884 | ||||
- Janux Therapeutics doses first patient in JANX013 Phase 1 trial
- Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
- Wolfe Research Upgrades Janux Therapeutics (JANX) to Outperform, 'An ARM Out of the Penalty Box'
- TD Cowen Assumes Janux Therapeutics (JANX) at Buy
- Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.
- Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: Janus Henderson Group Ltd.
- Janux Therapeutics (JANX) PT Lowered to $35 at Stifel
- Janux Therapeutics, Inc. (JANX) Misses Q2 EPS by 8c
- Form 10-Q Janux Therapeutics, Inc. For: Jun 30
- Form 8-K Janux Therapeutics, Inc. For: Aug 06
Entities mentioned with JANX
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Cowen & Co | View Related Stories »
- FDA | View Related Stories »
- William Blair | View Related Stories »
- Show More...
